Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895618 · ClinicalTrials.gov registry record · NA
The Effect of the Erchonia GVL Low Level Laser Therapy on Neck and Shoulder Pain
A NA study, sponsored by Erchonia Corporation.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT04895618: Completed NA study, sponsored by Erchonia Corporation.
NCT04895618 is a NA study that has completed, run by Erchonia Corporation. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04895618, a NA study, has completed, sponsored by Erchonia Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is to see if applying green and violet low level laser light to the neck and shoulders can help to reduce pain in the neck and shoulders.
Primary Outcome
The Visual Analog Scale (VAS) from one day, baseline to endpoint measurement (following 13-minute treatment administration) is calculated for each subject. Individual subject success is defined as a 30% or greater change in VAS pain scores across the evaluation period. A negative (-) percent change indicates a decrease in pain level and is positive for individual subject success. A positive (+) percent change indicates an increase in pain level and is negative for individual subject success. Ov
Interventions
- DEVICE Erchonia GVL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2020-11-11 |
| Est. Completion | 2022-05-20 |
| Phase | NA |
What the finished NCT04895618 record still lists
NCT04895618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Erchonia GVL is the first listed.
NCT04895618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04895618 about?
NCT04895618 is a clinical study titled "The Effect of the Erchonia GVL Low Level Laser Therapy on Neck and Shoulder Pain". This study is to see if applying green and violet low level laser light to the neck and shoulders can help to reduce pain in the neck and shoulders.
What is the current status of trial NCT04895618?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2020-11-11. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT04895618?
The interventions under investigation include: Erchonia GVL (DEVICE).
Who is sponsoring clinical trial NCT04895618?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04895618's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI